![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1486406
¼¼°èÀÇ Ãʱ⠵¶¼º ½ÃÇè ½ÃÀå ±Ô¸ð Á¶»ç : ±â¼úº°, µ¶¼º Æò°¡ÁöÇ¥º°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)Global Early Toxicity Testing Market Size study, by Technique, by Toxicity Endpoint, by End User and Regional Forecasts 2022-2032 |
¼¼°è Ãʱ⠵¶¼º ½ÃÇè ½ÃÀåÀº 2023³â ¾à 12¾ï 1,000¸¸ ´Þ·¯ ±Ô¸ð¿¡ ´ÞÇßÀ¸¸ç, ¿¹Ãø ±â°£ÀÎ 2024³âºÎÅÍ 2032³â±îÁö 8.53% ÀÌ»óÀÇ °ßÁ¶ÇÑ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.
Ãʱ⠵¶¼º ½ÃÇèÀº ½Å¾à °³¹ß °úÁ¤¿¡¼ Áß¿äÇÑ ´Ü°èÀ̸ç, »õ·Î¿î ÈÇÕ¹°À̳ª ¹°ÁúÀÌ »ý¹°Ã¼¿¡ ¹ÌÄ¥ ¼ö ÀÖ´Â ÀáÀçÀûÀÎ ºÎÀÛ¿ëÀ» Æò°¡ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ÀÌ ¿¹ºñ Æò°¡´Â ¾ÈÀü¼º ¹®Á¦¸¦ ÆÄ¾ÇÇÏ¿© ÈÄ¼Ó ¿¬±¸°³¹ß¿¡ µµ¿òÀ» ÁÝ´Ï´Ù. Ãʱ⠵¶¼º½ÃÇèÀ» ÅëÇØ R&D´Â ÀǾàǰ Èĺ¸¹°ÁúÀ» Ãß°¡ °³¹ß ´Ü°è·Î ³Ñ¾î°¡±â Àü¿¡ À§ÇèÀ» ÁÙÀÌ°í ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» ÃÖÀûÈÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼¼°è Ãʱ⠵¶¼º ½ÃÇè ½ÃÀåÀº ½ÅÈï±¹µéÀÇ ¿¬±¸°³¹ß¿¡ ´ëÇÑ °ü½É Áõ°¡¿Í »ý¸íÀ» À§ÇùÇÏ´Â Áúº´¿¡ ´ëÇÑ Çõ½ÅÀûÀÎ ÀǾàǰ ¹× ±â¼ú °³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡·Î ÀÎÇØ À¯¸ÁÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.
´ç´¢º´, ¾Ï, ½ÉÇ÷°ü Áúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ »õ·Ó°í È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ ¾ÈÀü¼ºÀ» º¸ÀåÇϱâ À§ÇØ ±¤¹üÀ§ÇÑ µ¶¼º ½ÃÇè°¡ ÇÊ¿äÇØÁü¿¡ µû¶ó Àü ¼¼°è Ãʱ⠵¶¼º ½ÃÇè ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãʱ⠵¶¼º ½ÃÇè ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä ±ÞÁõÀº ¼ÒºñÀÚ Àνİú ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã·Î ÀÎÇØ ½Äǰ °¡°ø ¹× ¾ÈÀü º¸Àå¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´õ¿í ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª Ãʱ⠵¶¼º ½ÃÇè°ú °ü·ÃµÈ ³ôÀº ºñ¿ë, ƯÈ÷ ´Ù¾çÇÑ »ý¹°Ã¼¿Í ¿©·¯ Á¾¸»Á¡À» Æ÷ÇÔÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÇèÀÇ °æ¿ì, ƯÈ÷ ÀڱݷÂÀÌ ºÎÁ·ÇÑ Áß¼Ò±â¾÷¿¡°Ô´Â Å« À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹Ì±¹ FDA ¹× À¯·´ÀǾàǰû(EMA)°ú °°Àº ±â°üÀÇ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀº ½Å¾à ½ÂÀÎ °úÁ¤À» Áö¿¬½ÃŰ°í ½ÃÀå ÁøÀÔÀ» Áö¿¬½ÃÅ´À¸·Î½á ¼¼°è Ãʱ⠵¶¼º ½ÃÇè ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
À̹ø Ãʱ⠵¶¼º ½ÃÇè ¼¼°è ½ÃÀå Á¶»ç¿¡¼ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, Áß³²¹Ì, ±âŸ Áö¿ªÀ̸ç, 2023³â¿¡´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå Å« Áö¿ª ½ÃÀåÀ¸·Î ºÎ»óÇß½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¬±¸ °³¹ß(R&D) Ȱµ¿¿¡ ´ëÇÑ °·ÂÇÑ ÁýÁß°ú ÀϺ», Çѱ¹, È£ÁÖ µîÀÇ ±¹°¡¿¡¼ÀÇ ºÎ¹® È®´ë·Î ÀÎÇØ Ãʱ⠵¶¼º ½ÃÇè(ETT) »ê¾÷À» ¼±µµÇÒ Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áß±¹, Àεµ, ÀϺ», Çѱ¹ µî ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀϺΠ±¹°¡¿¡¼ ³úÁ¹Áß ¹ß»ý·üÀÌ Áõ°¡ÇÏ¸é¼ ETT »ê¾÷ÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ³úÁ¹ÁßÀº ³úÁ¹Áß È¯ÀÚ¸¦ À§ÇÑ ½Å¾à ¹× Ä¡·á¹ý °³¹ß¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ Ãʱ⠵¶¼º ½ÃÇè¿¡ ÀÖ¾î Áß¿äÇÑ °ü½É ºÐ¾ßÀÔ´Ï´Ù. National Center for Biotechnology Information¿¡ µû¸£¸é, 2022³â 3¿ù ÇöÀç 40¼¼ ÀÌ»ó Áß±¹ÀÎÀÇ ³úÁ¹Áß ¹ßº´ °Ç¼ö´Â 3,400¸¸ °Ç, À¯º´ÀÚ ¼ö´Â 1,780¸¸ ¸í, ³úÁ¹Áß »ç¸ÁÀÚ ¼ö´Â 230¸¸ ¸í¿¡ ´ÞÇÕ´Ï´Ù. ÇÑÆí, ºÏ¹Ì´Â 2024³âºÎÅÍ 2032³â±îÁö ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â Áö¿ªÀÔ´Ï´Ù.
Global Early Toxicity Testing Market is valued at approximately USD 1.21 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 8.53% over the forecast period 2024-2032. Early toxicity testing is a critical phase in the drug development process, aimed at assessing the potential adverse effects of new compounds or substances on living organisms. This preliminary evaluation helps identify safety concerns and informs subsequent research and development efforts. By conducting early toxicity testing, researchers can mitigate risks and optimize the safety profile of pharmaceutical candidates before advancing them to further stages of development. The Global Early Toxicity Testing Market shows promising growth due to the heightened emphasis of developing countries on R&D and increased investments in innovative drug and technology development for life-threatening diseases.
The increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders has heightened the demand for new and efficacious treatments, necessitating extensive toxicological testing to ensure their safety driving the growth of the Global Early Toxicity Testing Market. This surge in demand for early toxicity testing services is further propelled by the rising need for food processing and safety assurance, driven by consumer awareness and regulatory scrutiny. However, the high costs associated with early toxicity testing, particularly for comprehensive studies involving diverse organisms and multiple endpoints, pose a significant barrier, particularly for smaller companies with limited financial resources. Moreover, stringent regulatory requirements set by agencies such as the US FDA and the European Medicines Agency lengthen the approval process for new drugs, potentially impeding Global Early Toxicity Testing Market growth due to delayed market entry.
The key regions considered for the Global Early Toxicity Testing market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, Asia Pacific was the largest regional market. The Asia-Pacific region is poised to lead the Early Toxicity Testing (ETT) industry, driven by its robust focus on Research and Development (R&D) activities and the expanding sector in nations such as Japan, South Korea, and Australia. Furthermore, the increasing incidence of strokes in specific countries within the Asia-Pacific region, including China, India, Japan, and South Korea, is fueling growth in the ETT industry. Stroke represents a critical area of concern for early toxicity testing, as it plays a pivotal role in the development of new drugs and therapies for stroke patients. According to the National Center for Biotechnology Information, as of March 2022, there were 34 million incident cases of stroke, 17.8 million prevalent cases, and 2.3 million deaths from stroke among the Chinese population aged 40 years and older. Whereas, North America is accounted as the fastest growing region over the forecast period of 2024-2032.